300255.SZ深圳证券交易所 · 创业板 ChiNext
Hebei Changshan Biochemical Pharmaceutical 常山药业
Chemical Pharmaceuticals 化学制药
¥23.11−¥0.52 · −2.20%
Open 开盘
¥23.98
High 最高
¥24.73
Low 最低
¥23.05
Prev Close 昨收
¥23.63
Volume 成交量
2,676.9万股
Turnover 成交额
¥6.38亿
Mkt Cap 总市值
¥212亿
P/E 市盈率
−61.5×
Recent Activity 近期动态All Filings 全部公告 →
5 significant filings since 29 May 2026: 3 on guarantee or financial assistance, 1 on pledge released and 1 on management change. The latest, on 22 Sep 2026: 关于全资子公司为公司提供担保的进展公告. 2 unverified reports logged, the latest on 23 Jun 2026.
自 29 May 2026 起有 5 份重大公告：guarantee or financial assistance 3 份、pledge released 1 份、management change 1 份。最新一份（22 Sep 2026）：关于全资子公司为公司提供担保的进展公告。记录了 2 条未经核实的报道，最新一条见于 23 Jun 2026。
30.0040.0050.0060.00
Volume 成交量
1.18亿
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Figures as filed, most recent period first. 按披露口径，最新一期在前。
| Line Item 项目 | 30 Jun 2026 中报 | 31 Mar 2026 一季报 | 31 Dec 2025 年报 | 30 Sep 2025 三季报 | 30 Jun 2025 中报 | 31 Mar 2025 一季报 |
|---|---|---|---|---|---|---|
| Revenue 营业收入 | ¥4.76亿 | ¥2.56亿 | ¥8.75亿 | ¥6.81亿 | ¥4.92亿 | ¥2.59亿 |
| Revenue YoY 营收同比 | −3.21% | −1.00% | −15.10% | −13.11% | −13.42% | −12.10% |
| Net Profit 净利润 | −¥1,676.2万 | ¥587.1万 | −¥3.58亿 | −¥4,481.7万 | −¥2,908.9万 | ¥378.3万 |
| Net Profit YoY 净利同比 | +42.38% | +55.21% | −43.46% | −714.77% | +37.98% | +106.13% |
|
Gross Margin
毛利率
The share of each sale left after the direct cost of making the product. It shows pricing power before overheads, marketing and tax. 每笔销售扣除直接生产成本后剩下的比例，反映管理费用、营销和税之前的定价能力。 Direction matters more than level, and a widening lead over peers signals a durable advantage. 方向比水平更重要，与同业差距持续拉大说明优势稳固。 | 21.62% | 24.60% | 15.13% | 15.91% | 14.54% | 23.10% |
|
Net Margin
净利率
The share of revenue left as profit after all costs, interest and tax. 扣除全部成本、利息和税后，营收中剩下的利润比例。 Compare within one industry, because a supermarket at 3% can be healthier than a software company at 15%. 只在同行业内比较：3% 的超市可能比 15% 的软件公司更健康。 | −4.57% | 1.32% | −41.99% | −8.36% | −7.37% | 0.63% |
|
Return on Equity
净资产收益率
The profit the company produced in the year for every 100 yuan that shareholders have in the business. 公司一年内为股东投入的每 100 元所赚取的利润。 A sustained 15% or more is good, provided it is not propped up by heavy borrowing. 持续 15% 以上为佳，前提是不靠高负债撑起来。 | −1.40% | 0.49% | −25.87% | −2.91% | −1.88% | 0.24% |
|
Debt Ratio
资产负债率
Total liabilities as a percentage of total assets. At 60%, lenders have funded three yuan of the business for every two from the owners. 总负债占总资产的百分比。60% 意味着贷款方每出三元，股东出两元。 Read it against the industry, as a bank sits above 90% and a distiller below 30%. 要对照行业来看：银行常在 90% 以上，白酒企业则在 30% 以下。 | 74.46% | 73.60% | 73.16% | 68.26% | 66.97% | 66.14% |
| Current Ratio 流动比率 | 0.75× | 0.74× | 0.69× | 0.87× | 0.79× | 0.82× |
|
Cash Flow to Revenue
经营现金流/营收
Cash the business collected from trading, as a multiple of the revenue it booked. 经营活动收到的现金与账面营收之比。 A figure well below the net margin, period after period, means sales are being booked faster than they are paid for. 如果连续多期明显低于净利率，说明销售确认快于回款。 | 0.04× | 0.08× | 0.06× | 0.21× | 0.35× | 0.40× |
|
Earnings per Share
每股收益
Total profit divided by the number of shares. It is the part of the year’s profit that belongs to one share. 净利润除以股份数，即一股所对应的年度利润。 Check whether the share count is falling, because buybacks raise EPS without raising profit. 留意股份数是否在减少：回购会抬高每股收益而利润并未增加。 | −¥0.02 | ¥0.01 | −¥0.39 | −¥0.05 | −¥0.03 | ¥0.00 |
|
Book Value per Share
每股净资产
The accounting value of what the company owns after debts, divided by the number of shares. 公司扣除负债后的账面价值除以股份数。 Divide the share price by it to get the price-to-book ratio. 用股价除以它就得到市净率。 | ¥1.29 | ¥1.32 | ¥1.31 | ¥1.65 | ¥1.67 | ¥1.70 |
Units 单位
Money is in CNY, in 亿 (100 million) and 万 (10,000). 货币为 CNY，单位为亿和万。
Periods Held 期数
10 periods, 31 Mar 2024 to 30 Jun 2026. 共 10 期，31 Mar 2024 至 30 Jun 2026。
Basis 口径
Interim and quarterly figures are cumulative from the start of the fiscal year. Year-on-year figures are as filed. 中期和季度数据为财年累计值，同比数据按披露口径。